Dr Jo Perry
PhD, BSc (Hons)
Dr Perry is a cell and molecular biologist with expertise in endocrinology and oncology. Her research interests lie in the involvement of growth factors and hormones in human development and disease including complications of pregnancy and cancer.
Dr Perry completed her PhD at the Institute of Cancer Research in London and was awarded a National Health and Medical Research Council (NHMRC) Peter Doherty Postdoctoral Fellowship to work at the Murdoch Childrens Research Institute in Melbourne. She joined the Liggins Institute in 2005.
Research | Current
- The role of placental growth hormone in the development and function of the placenta.
- The contribution of human growth hormone to cancer progression and the mechanistic interactions of this hormone with conventional cancer therapies used clinically.
- Developing small molecule targeted therapies directed against the human growth hormone receptor.
Other research and teaching interests
- Liggins Education Network for Science (LENScience)
- Auckland Cancer Research Network
Selected publications and creative works (Research Outputs)
- Liao, S., Vickers, M., Taylor, R., Jones, B., Fraser, M., McCowan, L., ... Perry, J. (2017). Maternal serum IGF-1, IGFBP-1 and 3, and placental growth hormone at 20 weeks' gestation in pregnancies complicated by preeclampsia. Pregnancy Hypertension, 10, 149-154. 10.1016/j.preghy.2017.07.148
Other University of Auckland co-authors: Mhoyra Fraser, Mark Vickers, Lesley McCowan, Philip Baker, Beatrix Jones
- Reynolds, C. M., Perry, J. K., & Vickers, M. H. (2017). Manipulation of the growth hormone-insulin-like growth factor (GH-IGF) axis: A treatment strategy to reverse the effects of early life developmental programming. International Journal of Molecular Sciences, 18 (8).10.3390/ijms18081729
Other University of Auckland co-authors: Mark Vickers, Clare Reynolds
- Perry, J. K., Wu, Z.-S., Mertani, H. C., Zhu, T., & Lobie, P. E. (2017). Tumour-derived human growth hormone as a therapeutic target in oncology. Trends in Endocrinology & Metabolism, 28 (8), 587-596. 10.1016/j.tem.2017.05.003
- Liao, S., Vickers, M., Taylor, R., Jones, B., Fraser, M., McCowan, L., ... Perry, J. (2016). Human placental growth hormone is increased in maternal serum at 20 weeks of gestation in pregnancies with large-for-gestational-age babies. Growth Factors, 34 (5-6), 203-209. 10.1080/08977194.2016.1273223
Other University of Auckland co-authors: Mark Vickers, Mhoyra Fraser, Lesley McCowan, Philip Baker, Beatrix Jones
- Evans, A., Jamieson, S. M. F., Liu, D. X., Wilson, W. R., & Perry, J. K. (2016). Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model. Cancer Letters, 379 (1), 117-123. 10.1016/j.canlet.2016.05.031
Other University of Auckland co-authors: William Wilson, Stephen Jamieson
- Vouyovitch, C. M., Perry, J. K., Liu, D. X., Bezin, L., Vilain, E., Diaz, J. J., ... Mertani, H. C. (2016). WNT4 mediates the autocrine effects of growth hormone in mammary carcinoma cells. Endocrine-Related Cancer, 23 (7), 571-585. 10.1530/ERC-15-0528
- Kong, X., Wu, W., Yuan, Y., Pandey, V., Wu, Z., Lu, X., ... Zhang, M. (2016). Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma. Oncotarget, 7 (20), 29465-29479. 10.18632/oncotarget.8781
- Jiang, Y., Marshall, R., Walpole, S., Prieto-Merino, D., Liu, D.-X., & Perry, J. (2015). An international ecological study of adult height in relation to cancer incidence for 24 anatomical sites. Cancer Causes & Control, 26 (3), 493-499. 10.1007/s10552-014-0520-1
Other University of Auckland co-authors: Yannan Jiang, Roger Marshall